Scott Penfold

Dr. Scott Penfold

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ASAlexandre Santos
Alexandre Santos
SPScott Penfold
Scott Penfold
PGPeter Gorayski
Peter Gorayski
HLHien Le
Hien Le
Hypofractionated radiotherapy is an attractive approach for minimizing patient burden and treatment cost. Technological advancements in external beam radiotherapy (EBRT) delivery and image guidance have resulted in improved targeting and conformality of the absorbed dose to the disease and a reduction in dose to healthy tissue. These advances in EBRT have led to an increasing adoption and interest in hypofractionation. Furthermore, for many treatment sites, proton beam therapy (PBT) provides an improved absorbed dose distribution compared to X-ray (photon) EBRT. In the past 10 years there has been a notable increase in reported clinical data involving hypofractionation with PBT, reflecting the interest in this treatment approach. This review will discuss the reported clinical data and radiobiology of hypofractionated PBT. Over 50 published manuscripts reporting clinical results involving hypofractionation and PBT were included in this review, ~90% of which were published since 2010. The most common treatment regions reported were prostate, lung and liver, making over 70% of the reported results. Many of the reported clinical data indicate that hypofractionated PBT can be well tolerated, however future clinical trials are still needed to determine the optimal fractionation regime.

1 June 2015 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
MDMichael Douglass
Michael Douglass
SPScott Penfold
Scott Penfold
EBEva Bezak
Eva Bezak
The major differences between the physics models in Geant4-DNA and RITRACKS Monte Carlo packages are investigated. Proton and electron ionisation interactions and electron excitation interactions in water are investigated in the current work. While these packages use similar semiempirical physics models for inelastic cross-sections, the implementation of these models is demonstrated to be significantly different. This is demonstrated in a simple Monte Carlo simulation designed to identify differences in interaction cross-sections.

23 February 2024 in Journal of Medical Radiation Sciences
Verified
Journal Article
Open access
SPScott Penfold
Scott Penfold
ASAlexandre M. C. Santos
Alexandre M. C. Santos
MPMelanie Penfold
Melanie Penfold
ESEmma Shierlaw
Emma Shierlaw
RCRosanna Crain
Rosanna Crain
Introduction: Because of the co‐location of critical organs at risk, base of skull tumours require steep dose gradients to achieve the prescribed dosimetric criteria. When available, proton beam therapy (PBT) is often considered a desirable modality for these cases, but in many instances, compromises in target coverage are still required to achieve critical organ at risk (OAR) tolerance doses. A number of techniques have been proposed to further improve the penumbra of PBT. In the current study, we propose a novel, collimator‐free treatment planning technique that combines high‐energy shoot‐through proton beams with conventional Bragg peak spot placement. The small spot size of the high‐energy pencil beams provides a sharp penumbra at the target boundary, and the Bragg peak spots provide a higher linear energy transfer (LET) boost to the target centre.Methods: Three base of skull chordoma patients were retrospectively planned with three different PBT treatment planning techniques: (1) conventional intensity‐modulated proton therapy (IMPT); (2) high‐energy proton arc therapy (HE‐PAT); and (3) the novel technique combining HE‐PAT and IMPT, referred to as single high‐energy arc with Bragg peak boost (SHARP). The Monaco 6 treatment planning system was used.Results: SHARP was found to improve the PBT penumbra in the plane perpendicular to the HE‐PAT beams. Minimal penumbra differences were observed in the plane of the HE‐PAT beams. SHARP reduced dose‐averaged LET to surrounding organs at risk.Conclusion: A novel PBT treatment planning technique was successfully implemented. Initial results indicate the potential for SHARP to improve the penumbra of PBT treatments for base of skull tumours.

1 February 2023 in Journal of Medical Imaging and Radiation Oncology
Verified
Journal Article
Open access
SPScott Penfold
Scott Penfold
MDMikaela Dell'Oro
Mikaela Dell'Oro
PGPeter Gorayski
Peter Gorayski
EHEunji Hwang
Eunji Hwang
HLHien Le
Hien Le
AYAdam Yeo
Adam Yeo
Proton-to-photon comparative treatment planning is a current requirement of Australian Government funding for patients to receive proton beam therapy (PBT) overseas, and a future requirement for Medicare funding of PBT in Australia. Because of the fundamental differences in treatment plan creation and evaluation between PBT and conventional radiation therapy with x-rays (XRT), there is the potential for a lack of consistency in the process of comparing PBT and XRT treatment plans. This may have an impact on patient eligibility assessment for PBT. The objective of these guidelines is to provide a practical reference document for centres performing proton-to-photon comparative planning and thereby facilitate national uniformity.

6 June 2022 in Medical Physics
Verified
Journal Article
Open access
SPScott Penfold
Scott Penfold
Background: Proton imaging makes use of high‐energy, low‐intensity proton beams that fully traverse the patient and has been suggested to reduce range uncertainty in proton therapy. Upright patient positioning with proton imaging is being considered for a fixed beam room of a new proton therapy facility currently under construction. Considering that the yield and energy spectrum of secondary radiation from high‐energy proton beams is proton beam energy dependent, an assessment of radiation shielding at the energies required for proton imaging should be performed prior to use. Furthermore, NCRP 144 recommends that pion production be considered for proton energies greater than 300 MeV, which are not typically utilized for proton therapy but may be required for proton imaging.Purpose: The purpose of this work was to determine whether proton treatment and imaging with an upright patient positioning system on a fixed beamline were acceptable from a radiation shielding perspective. This is the first report on radiation shielding assessment of proton imaging applications and includes consideration of pion production at the proton beam energy of 330 MeV.Methods: The Geant4 Monte Carlo toolkit was used for the radiation shielding assessment. The calculations consisted of the generation of secondary particle phase‐space files by simulating the passage of high‐energy proton beams in two target materials, and subsequent simulation of the secondary particles in the proton therapy facility geometry. Particle fluence was converted to operational and protection radiation safety quantities with a custom python script for assessment of instantaneous and annual doses, respectively.Results: The total yields of pions from a 330‐MeV proton beam were many orders of magnitude less than that of neutrons and photons. Three‐dimensional maps of ambient dose rate for a 330‐MeV proton beam showed doses arising from secondary neutrons and photons far exceed those arising from pion production. Incorporating representative annual workloads into the calculation demonstrated that proton imaging doses outside the shielded area were negligible compared to those arising from proton therapy.Conclusions: Pion production has a negligible impact on the radiation shielding of proton imaging at 330 MeV relative to neutron and photon production. Radiation shielding designed for proton therapy is adequate for high‐energy proton imaging applications.

1 December 2023 in Journal of Medical Radiation Sciences
Verified
Journal Article
Open access
ESEmma Shierlaw
Emma Shierlaw
MPMelanie Penfold
Melanie Penfold
RCRosanna Crain
Rosanna Crain
ASAlexandre M.C. Santos
Alexandre M.C. Santos
SPScott Penfold
Scott Penfold
Introduction: Australia's first proton beam therapy (PBT) centre will house a fixed‐beam room and two gantry rooms. As the only PBT facility in Australia for at least the short term, there is a need to efficiently allocate treatment appointments between the gantry and fixed‐beam rooms. This planning study assesses the dosimetric differences between fixed‐beam and gantry‐based treatment plans for base of skull chordoma, one of the core indications likely to be referred for PBT in Australia.Methods: Retrospective gantry‐based and fixed‐beam treatment plans were generated for five patients with base of skull chordoma. Fixed‐beam plans were generated with a conventional horizontal patient positioning system. Robust intensity modulated proton therapy (IMPT) optimisation and evaluation techniques were used for both delivery systems. Plans were designed to maximise target coverage while adhering to maximum dose constraints to neighbouring critical organs at risk.Results: Robust target coverage and integral dose were found to be approximately equivalent for the gantry‐based and fixed‐beam plans. Doses to specific organs at risk could be reduced with the gantry‐based geometry; however, the gantry‐based plans did not exhibit a general decrease in doses to organs at risk.Conclusion: A fixed‐beam treatment plan was found to be non‐inferior to a gantry‐based treatment plan for all base of skull patients included in the current study.